...
首页> 外文期刊>Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society >Combined side‐by‐side and stent‐in‐stent method for triple metal stenting in patients with malignant hilar biliary obstruction
【24h】

Combined side‐by‐side and stent‐in‐stent method for triple metal stenting in patients with malignant hilar biliary obstruction

机译:恶性Hilar胆管障碍患者三重金属支架的并排和支架依章方法

获取原文
获取原文并翻译 | 示例

摘要

Background and Aim Endoscopic placement of three branched self‐expandable metallic stents ( SEMS ) for high‐grade malignant hilar biliary obstruction ( MHBO ) is technically challenging. We examined the feasibility and efficacy of a novel stenting method combining side‐by‐side and stent‐in‐stent ( SBSIS ) placement for MHBO . Methods Between January 2015 and December 2018, 27 consecutive patients with high‐grade MHBO underwent SBSIS placement. We evaluated the technical success, functional success, recurrent biliary obstruction ( RBO ), adverse events other than RBO , and reintervention success rates associated with SBSIS placement. Results Technical success rate was 85% (23/27). Insertion of the third SEMS failed in four patients, and median diameter of the common bile duct ( CBD ) was significantly smaller in patients in whom technical failure occurred (5?mm vs 8?mm; P ?=?0.004). Functional success was achieved in all patients in whom the procedure was a technical success. Rate of adverse events other than RBO was 15% (4/27). RBO rate was 43% (10/23), and median time to RBO was 157?days. Success rate of endoscopic reintervention for RBO was 89% (8/9). Conclusion SBSIS placement showed favorable results and is a promising option in patients with high‐grade MHBO requiring triple metal stenting. However, it might be preferable to avoid SBSIS in patients with a narrow CBD . Clinical Trial Registry: UMIN000035721
机译:用于高级恶性Hilar胆道阻塞(MHBO)的三个分支自膨胀金属支架(SEMS)的背景和目标内窥镜放置在技术上挑战。我们研究了一种新型支架方法的可行性和功效,其组合并排支架(SBSIS)放置的MHBO。方法2015年1月至2018年12月,连续27名高档MHBO患者进行了SBSI安置。我们评估了技术成功,功能成功,复发性胆道障碍(RBO),rbo以外的不良事件,以及与SBSI安置相关的重新实施成功率。结果技术成功率为85%(23/27)。在发生技术失效的患者中,四名患者的第三个患者的插入失败,常见的胆管(CBD)的中值显着更小(5?mm与8?mm; p?= 0.004)。所有患者都取得了功能的成功,该患者是技术成功的。 rbo以外的不良事件率为15%(4/27)。 RBO率为43%(10/23),rbo的中位时间为157?天。 RBO的内窥镜再发明内的成功率为89%(8/9)。结论SBSIS展示率显示出有利的结果,是高档MHBO患者需要三重金属支架的有前途的选择。然而,可能优选避免患有狭窄CBD的患者的SBSI。临床试验登记处:UMIN000035721

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号